Reaction #68047

ord-473148dd016b4c6ba71b60824cefb0a1

Solvents

Conditions

Detailed conditions
See reaction.notes.procedure_details.

Workup

  1. 1
    workup.ADDITIONwas added
  2. 2
    OtherThe solvent was removed under reduced pressure, and aqueous saturated sodium hydrogen carbonate solution and chloroform
  3. 3
    workup.ADDITIONwere added
  4. 4
    OtherThe organic layer was separated
  5. 5
    Extractionthe aqueous layer was extracted with chloroform
  6. 6
    Washwashed with aqueous saturated sodium chloride solution
  7. 7
    Dryingdried over anhydrous magnesium sulfate
  8. 8
    Otherthe solvent was removed under reduced pressure
  9. 9
    OtherThe residue thus obtained
  10. 10
    Otherwas purified by silica gel column chromatography [eluent; chloroform:methanol=10:1]

Procedure

To 2 mL of a chloroform solution containing 0.25 g of methyl 1-(2-(4-((tert-butoxycarbonyl)(2,3-dihydro-1,4-benzodioxin-6-ylmethyl)amino)piperidin-1-yl)ethyl)-7-methoxy-2-oxo-1,2-dihydroquinoline-4-carboxylate, 2 mL of trifluoroacetic acid was added and stirred for 16 hours. The solvent was removed under reduced pressure, and aqueous saturated sodium hydrogen carbonate solution and chloroform were added. The organic layer was separated, and the aqueous layer was extracted with chloroform. The organic layer and extracts were combined, washed with aqueous saturated sodium chloride solution, dried over anhydrous magnesium sulfate, and the solvent was removed under reduced pressure. The residue thus obtained was purified by silica gel column chromatography [eluent; chloroform:methanol=10:1] to give 0.12 g of methyl 1-(2-(4-((2,3-dihydro-1,4-benzodioxin-6-ylmethyl)amino)piperidin-1-yl)ethyl)-7-methoxy-2-oxo-1,2-dihydroquinoline-4-carboxylate as a white solid.

Source

DOI: 10.6084/m9.figshare.5104873.v1Patent: US08524738B2uspto-grants-2013_09